Myelodysplastic syndromes (MDS) are a heterogenous group of acquired hematopoietic stem cell disorders. Refractory cytopenia (RC) is the most common subtype of childhood MDS and hematopoietic stem cell transplantation (HSCT) is the only curative treatment. HSCT following a myeloablative preparative regimen is associated with a low probability of relapse and considerable transplant-related mortality. In the present European Working Groups of MDS pilot study, we investigated whether a reduced intensity conditioning regimen (RIC) is able to offer reduced toxicity without increased rates of graft failure or relapse. Nineteen children with RC were transplanted from an unrelated donor following RIC consisting of fludarabine, thiotepa and anti-thymocyte globulin. Three patients experienced graft failure. Neutrophil and platelet engraftment occurred at a median time of 23 and 30 days, respectively. Cumulative incidence of grade II-IV and grade III and IV acute graft-versus-host disease (GVHD) was 0.48 and 0.13, respectively; three patients developed extensive chronic GVHD. Although infections were the predominant complications, only one patient with extensive chronic GVHD died from infectious complications. Overall and event-free survival at 3 years were 0.84 and 0.74, respectively. In conclusion, our results were comparable to those of patients treated with myeloablative HSCT. Long-term follow-up is needed to demonstrate the expected reduction in long-term sequelae.
Introduction
Myelodysplastic syndrome (MDS) comprises a heterogeneous group of acquired hematopoietic stem cell disorders characterized by peripheral blood (PB) cytopenia and ineffective dysplastic hematopoiesis. Refractory cytopenia (RC), defined as myelodysplasia without increased blasts, is the most common subtype of childhood MDS. 1 In the studies of the European Working Groups of MDS (EWOG-MDS), about three quarters of children with RC have a hypocellular bone marrow (BM) biopsy. 2 The presence of monosomy 7 is the most important predictive factor for progression to advanced MDS. 3 By contrast, children with RC without cytogenetic abnormalities may experience a long stable course of their disease. To date, hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with RC. HSCT following a myeloablative preparative regimen is associated with a low probability of relapse. 4 Hence, transplant-related mortality has been the major cause of treatment failure, specifically in patients transplanted from an unrelated donor (UD). 4, 5 The use of a reduced intensity conditioning regimen (RIC) represents an effective strategy to reduce the toxicity of transplantation, as shown in canine transplantation models 6 and in older debilitated patients with hematologic malignancies. 7, 8 Thus, it may be an attractive approach for UD HSCT in RC. Here, we report the results of 19 children with hypocellular RC who were transplanted from an UD after RIC with fludarabine, thiotepa and anti-thymocyte globulin (ATG).
Patients and methods
All patients reported were enrolled in the observational study EWOG-MDS 98 and diagnosed with RC with hypocellular BM. PB smears, BM aspirates and biopsies were assessed by central morphology review according to published criteria. 9 HSCT was recommended if the patients developed neutropenia (absolute neutrophil counto1000/ml) or transfusion dependency for red blood cells and/or platelets. In 2000, an interim analysis of study EWOG-MDS 98 demonstrated absence of relapse but considerable transplant-related mortality for patients with RC transplanted from a UD following a myeloablative regimen. Therefore, patients with RC considered at low risk of relapse as defined by presence of normal karyotype and decreased BM cellularity were subsequently offered a RIC UD transplant. HSCT for the 19 consecutive patients was performed between July 2001 and May 2005 in 10 European centers. Data were reported on standardized data collection forms to the Coordinating Study Center of the EWOG-MDS Study group. Informed consent was obtained according to the Declaration of Helsinki and the study was approved by the Institutional Review Board of each participating institution.
Patient characteristics
At diagnosis, median age of the 11 males and 8 females was 11.7 years (range 1.8-17.3), and median values for hemoglobin, platelet count and white blood cell count were 87 g/l (range 34-144), 25 Â 10 9 /l (range 8-125) and 2.9 Â 10 9 /l (1.0-8.4), respectively. Standard cytogenetics revealed a normal karyotype in 14 patients, was unsuccessful in four, and not performed in one. In the latter five patients, monosomy 7 and trisomy 8 had been excluded by fluorescence in situ hybridization. Karyotyping was repeated and found to be normal before HSCT in 12 patients, including one with previous unsuccessful studies. Before HSCT, transfusion dependency for red blood cells and/or platelets was noted in 16 patients, 13 had an absolute neutrophil count below 1.0 Â 10 9 /l. Transplantation procedure HSCT from UD was performed after a median interval of 11 months (range 3.0-111.1) from diagnosis. With lowresolution molecular typing for human leukocyte antigen (HLA)-A, -B and -C loci and high-resolution typing for DRB1 alleles, 14 donor-recipient pairs were completely matched, while 5 had disparities at the HLA-C (n ¼ 3) or HLA-A (n ¼ 2) locus (Table 1) . Fourteen patients were grafted with unmanipulated BM, while five received unmanipulated PB stem cells (PBSC). The median dose of CD34 þ cells was 3.0 Â 10 6 /kg bw (range 0.7-16.8). The preparative regimen consisted of thiotepa 5 mg/kg bw (day À8 to À6) and fludarabine 40 mg/m 2 (day À5 to À2). While the recommended dose of ATG was ATG Fresenius rabbit 60 mg/kg bw or an equivalent dose of a different ATG preparation, the dosage of ATG administered varied considerably (Table 1) . Graft-versus-host disease (GVHD) prophylaxis included short-course methotrexate and cyclosporine A in all patients. Donor cell chimerism was determined by PCR of short tandem repeats in PB and BM. 10 Median number of chimerism analyses per patient was 7 (range 2-31). Supportive therapy and surveillance for infections was performed according to the standards of each transplant center.
Definitions and statistical analysis Engraftment and acute GVHD were defined as reported previously. 11 Children alive with sustained donor cell engraftment at day 100 after HSCT were considered at risk for chronic GVHD, which was classified according to published criteria. 12 Overall survival (OS) was defined as the time from HSCT to death or last follow-up. Event-free survival (EFS) was defined as the time from HSCT to any event (graft failure, relapse of MDS or death from any cause whichever occurred first) or last follow-up. The Kaplan-Meier method was used for survival analysis. All results are expressed as 3-year probability and 95% confidence interval.
Acute and chronic GVHD were calculated as cumulative incidence taking into account competing risks. 13 For acute GVHD, relapse, death and either rejection or graft failure were treated as competing events, while patients alive and relapse-free at day þ 100 without having experienced acute GVHD were censored. For chronic GVHD, only patients surviving in remission and with donor engraftment for at least 100 days were evaluated. For chronic GVHD, relapse, death and either rejection or graft failure were considered competing events, data being censored at the time of last follow-up for patients who did not experience chronic GVHD. The statistical analysis was performed in August 2006. CD34 þ /kg bw) from a matched donor, the other with BM (2.8 Â 10 6 CD34 þ /kg bw) from a one antigen-mismatched donor. Both patients were regrafted from a different matched or one antigen-mismatched UD. The first patient received a fully myeloablative conditioning with busulfan, melphalan, cyclophosphamide and ATG and is alive with stable engraftment. The second patient was reconditioned with fludarabine, cyclophosphamide and ATG and died 99 days after first HSCT from Epstein-Barr virus (EBV)-induced lymphoproliferative disease (LPD). Secondary graft failure was seen in one patient transplanted with a low number (0.72 Â 10 6 CD34 þ /kg bw) of BM progenitors. This patient was successfully regrafted with PBSC (8 Â 10 6 CD34 þ /kg bw) of the same donor after preparation with fludarabine and ATG. The median time to achieve 0.5 Â 10 9 /l neutrophils in the 17 patients with primary engraftment was 23 days (range 16-35) (Figure 1) .
Of the 17 patients with neutrophil engraftment, 13 patients reached a self-sustained platelet count higher than 20 Â 10 9 /l in a median time of 30 days (range 16-201) (Figure 1 ). The patient with secondary graft failure had not reached a self-sustained platelet count before regrafting, one patient died of transplant-related causes on day 75 before platelet engraftment, and two patients required a CD34 þ cell boost of the same donor 226 and 315 days after HSCT. With the exception of the three children with graft failure all patients had full donor chimerism at all time points.
Graft-versus-host-disease The cumulative incidence of grade II-IV and grade III and IV acute GVHD in the 17 evaluable patients was 0.48 and 0.13, respectively. Grade III and IV acute GVHD developed in one of 13 patients at risk grafted from a fully matched donor and in one of four patients at risk grafted from a one antigen-disparate donor. Stem cell source of the two patients with grade III and IV acute GVHD was BM and PB, respectively. Three of the 16 patients at risk developed extensive chronic GVHD, including one grafted from a donor with a disparity in the HLA-C locus. Stem cell source was BM in all three patients. Interestingly, the two patients with grade III and IV acute GVHD and 2 of the 3 patients with extensive chronic GVHD had received ATG Fresenius rabbit 20-40 mg/kg bw instead of the recommended dose of 60 mg/kg bw.
Infections
Infections were the most prevalent complication observed. Significant bacterial, fungal and viral infections were diagnosed in 5, 2 and 8 patients, respectively. Five patients had bacterial sepsis that was successfully treated in all cases. Out of five patients with clinical and/or radiological signs of pneumonia, two were of fungal origin (both Aspergillus). One patient fully recovered after long-term antifungal therapy, the other remains on antifungal therapy for pulmonary aspergillosis 2 years after HSCT. Five patients experienced cytomegalovirus (CMV) reactivation/ infection with one of them developing CMV disease. This patient had extensive chronic GVHD and subsequently died from CMV and adenovirus infection. EBV viremia was detected in four cases. However, EBV surveillance was not performed in all centers. Two out of these four patients developed EBV-induced LPD and were successfully treated with rituximab alone or in combination with foscarnet.
OS and EFS
Sixteen patients are alive with a median follow-up of 17 months (range 8 months to 4.1 years); three patients died. One patient died of veno-occlusive disease 73 days after HSCT from a matched donor. This patient had previously received immunosuppressive therapy without response and was transplanted 3 years after initial diagnosis. Another patient, grafted from a C locus mismatched donor, developed extensive chronic GVHD and, as mentioned above, died of CMV and adenovirus infection. The third patient had experienced primary graft failure, and died of EBV-induced LPD following the second HSCT. Two additional patients had primary and secondary graft failure, respectively, but were successfully regrafted. 
Discussion
RIC is a novel approach to transplantation, extensively investigated for the treatment of patients with malignancies who are considered ineligible for a standard allograft either because of age or poor medical condition. It is based on immunosuppression, usually achieved by the use of purine analogs like fludarabine in combination with limited host myeloablation delivered by low-dose TBI or reduced doses of alkylating agents. In this pilot study, we combined fludarabine with thiotepa (15 mg/kg bw), because thiotepa has little organ toxicity outside of the BM. RIC may be able to not only reduce the risk of transplant-related lifethreatening complications but also the incidence of late effects. 6, 8 This is of particular interest for HSCT in children which is often followed by impaired growth and fertility. The reduction of early and late toxicity of RIC may be counterbalanced by an increased incidence of delayed engraftment, graft failure, mixed chimerism and relapse.
Because transplant-related mortality is the main cause of treatment failure in RC, HSCT with RIC is a particularly attractive approach in this disorder. Two primary and one secondary graft failure were observed among the 19 patients treated. All three patients received a second HSCT; two are alive with engraftment and one died of EBV-LPD. Low degree of immunosuppression, transplant from a mismatched or matched UD and transplantation of a low number of hematopoietic stem cells have previously been identified as risk factors for graft failure. 14, 15 In our series, the conditioning regimen included fludarabine and a standard dose of ATG (ATG Fresenius rabbit 60 mg/kg bw) in all three patients with graft failure. Two out of three patients were transplanted from a fully matched UD, whereas one was transplanted from a UD with a mismatch in the HLA-C locus. In the patient with secondary graft failure, the low-dose of hematopoietic stem cells (0.72 Â 10 6 CD 34 þ cells/kg bw) transplanted may have contributed to the graft failure. Graft failure is a known risk of HSCT following RIC and other investigators reported similar rates of graft failure in children transplanted for malignant or non-malignant disease following a RIC. 14, 16, 17 In consequence, EWOG-MDS implemented strict criteria for the selection of donors and RIC is offered only if an optimal donor, that is, no or one allele mismatch with highresolution HLA typing, is available.
The median time to myeloid and platelet recovery observed here was slightly longer compared to other series of RIC 14, 16, 17 and myeloablative HSCT. 4, 5 Two patients needed a CD34 þ cell boost to reach platelet engraftment. The type of donor (UD) and stem cell source (predominantly BM) may have contributed to the delayed engraftment. The cumulative incidence of grade II-IV and III and IV acute GVHD was remarkably low considering that all patients were transplanted from an UD and that only lowresolution techniques were used for HLA class I loci typing. Also, the rate of chronic GVHD (3 out of 16 patients at risk) compares favorably with previously published results of HSCT after either RIC or myeloablative therapy. 4, 14, 17 Although the numbers are too small to draw firm conclusions, it is remarkable that among the five patients with grade III and IV acute and extensive chronic GVHD four had received less than 60 mg/kg ATG.
Infections were the most frequently observed complication. All bacterial and one of the fungal infections could be treated successfully, one patient with pulmonary aspergillosis remains on antifungal treatment. Five of the 19 patients had a CMV reactivation/infection, one patient developed CMV disease and subsequently died of adenovirus infection. The incidence of both CMV reactivation and disease is similar to that of previously published pediatric RIC series.
14,18 EBV reactivation and EBV LPD are well-known complications reported in some studies of RIC-HSCT for pediatric patients. 19 The use of ATG and the occurrence of acute GVHD have been identified as additional risk factors for these viral complications. 20, 21 Because not all our patients were screened for EBV viremia, the true incidence of EBV reactivation in this cohort remains unknown.
Sixteen out of the 19 patients are alive with a median follow-up of 13 months. The estimated OS and EFS at 3 years was 0.84 (0.68-0.99) and 0.74 (0.54-0.94), respectively. Recently, the Seattle group reported the results of HSCT from either an HLA-identical sibling or UD in a cohort of 27 children with RC. With a variety of myeloablative regimens, the estimated 3-year survival probability was 0.74. 5 Our own group reported a similar EFS for 28 children transplanted for RC from a sibling or UD following a myeloablative conditioning with busulfan, cyclophosphamide and melphalan. 4 The fludarabine-based RIC we employed in this cohort of RC patients without cytogenetic abnormalities and with a hypocellular BM provides results comparable to those obtained in patients transplanted following a myeloablative conditioning regimen.
To our knowledge, there are no data on RIC in RC with hypercellular BM. Because a high BM cellularity may imply a higher risk of graft failure after RIC-HSCT, this pilot study was restricted to hypocellular RC. Similarly, patients with known karyotypic changes were excluded from the study because clonal abnormalities may implicate a higher risk of relapse. Other potential risk factors like number of transfusions before SCT or the time interval between diagnosis and SCT could not be evaluated in our patient population owing to small sample size. In addition, follow-up of this study is too short to assess long-term effects on growth and fertility. It therefore remains to be determined whether patients conditioned with reduced intensity will experience fewer and/or less severe long-term sequelae.
